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Abstract
Effects of Lactobacillus plantarum
and Lactobacillus paracasei for the 
prevention and alleviation of 
zymosan-induced Irritable Bowel 
Syndrome in mice
Lim Song
Dept. of Environmental Health
The Graduate School of Public Health
Seoul National University
Irritable bowel syndrome (IBS) tops list of functional gastrointestinal 
disorder with worldwide prevalence rates. Patients with IBS present 
with abdominal pain and altered bowel habits as well as emotional 
anxiety and depression. Nevertheless, no gold standard for the 
II
treatment of IBS exists. However, it has become evident that altered gut 
microbiota composition and its functions are key pathophysiological 
factors along the gut–brain axis in IBS. Furthermore, a general decrease 
in lactobacillus and Bifidobacterium species abundance was identified 
in IBS patients. In this study, we aimed to evaluate the efficacy and 
effectiveness of mixed and single strain of Lactobacillus plantarum
KBL396 and Lactobacillus paracasei KBL382 in a mouse model of 
IBS. IBS-like symptoms were induced in mice by intracolonic injection 
with zymosan suspension for 3 consecutive days. Mice were divided 
into groups that received either (1) phosphate buffer (PBS) + PBS (2) 
PBS + zymosan (3) amitriptyline (AMT) + zymosan (4) L. plantarum
KBL396 + zymosan (5) L. paracasei KBL382 + zymosan (6) L. 
plantarum KBL396/ L. paracasei KBL382 + zymosan. Orally 
administered treatment was started 7 days prior to the zymosan 
injection and continued until they were sacrificed. We found that 
treatment of L. plantarum KBL396 and L. paracasei KBL382 altered 
inflammatory cytokines, BDNF, 5-HT, and SERT in the colon and brain 
at day 7 and day 14 after the zymosan injection. In addition, we also 
found that treatment of the selected Lactobacillus strains reduced 
anxiety-like behaviors in the open field and elevated plus maze. These
III
findings suggest that L. plantarum KBL396 and L. paracasei KBL382 
may attenuate IBS-like symptoms and improve anxiety-like behaviors.
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Irritable bowel syndrome (IBS) is the most common functional 
gastrointestinal disorder, affecting 7 to 21% of the world population [1]. 
Its characteristics of abdominal pain and altered bowel habits, including 
bloating and stool irregularities have a substantial impact on the lives of 
individual and society by impairing their quality of life as well as 
economic burden with medical coasts [2, 3]. However, despite its high 
prevalence and influences, the precise mechanism of pathogenesis and 
pathophysiology remains unclear with multifactorial etiology [4]. 
Moreover, because of its heterogeneous condition and absence of 
structural and biochemical abnormality, there is a lack of gold standard 
diagnostic criteria and medications to treat IBS [5]. 
IBS is also known as a disorder of the gut-brain axis. In 
patients with IBS, elevated psychological abnormalities, including 
higher level of anxiety and depression are observed [6]. Many studies 
have identified physiological and molecular modifications along with 
the gut-brain axis, which is correlated with gut microbiota and immune 
activation in IBS [7-10]. It also has been found that serotonin (5-HT) is 
an important neurotransmitter and involved in gastrointestinal motility 
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and sensitivity in bidirectional gut-brain interactions [11]. In patient 
with IBS, increased 5-HT and decreased serotonin transporter (SERT) 
has been observed in gastrointestinal tract [12-14]. Also, serotonin 3 
receptors (5-HT3) that response to released serotonin from 
enterochromaffin (EC) cells in the wall of the gut are well known to 
transmit signals encoding important sensations such as nausea and pain 
to the central nervous system (CNS) [15-16]. 5-HT3 antagonists are 
used as a treatment of IBS, and have been shown to improve symptoms 
of non-constipated (NC) or diarrhea-predominant (D) IBS efficiently in 
both men and women [17]. In animal study, 5HT3 antagonists also 
reduce colorectal distension and visceral hypersensitivity induced by 
harmful gut stimuli [18]. Another vital pain modulator, brain-derived 
neurotrophic factor (BDNF), have been discovered and studied in IBS. 
BDNF, a member of the neurotrophin family of growth factors, is 
highly upregulated in colonic biopsies from patients with IBS [19]. 
Several studies have shown that increased expression of BDNF in 
colonic mucosa is associated with visceral hypersensitivity, which is an 
important hallmark characteristic of IBS, whereas the inhibition of 
BDNF reduced the abdominal pain degree [20-22]. 
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Intestinal microbiota has been also recognized as one of 
pathophysiological factors of IBS. Current studies have suggested that 
intestinal microbiota plays critical roles and might contribute to the 
intestinal wall permeability, immune activation, and enteroendocrine 
signaling in gut-brain communication [23, 24]. In patients with IBS, the 
lower microbial diversity, especially decreased abundance of 
Bifidobacterium and Lactobacillus species and increased abundance of 
Ruminococcus torques, has been reported compared to healthy 
individuals [25-27]. Clinical trials have demonstrated that 
administration of probiotics could alleviate symptoms of IBS in 
patients [28]. Moreover, an animal study has shown that the 
combination of Lactobacillus helveticus and Bifidobacterium longum
regulated hypothalamic-pituitary-adrenal (HPA) axis by glucocorticoid 
negative feedback and attenuated stress-induced visceral pain [29]. In 
addition, intestinal microbiota is associated with the decreased level of 
proinflammatory cytokines TNF-α, IL-1β, IFN-γ in IBS [30]. Although 
underlying pathophysiological mechanisms of the intestinal microbiota 
contributions to IBS are not fully understood, these findings have 
resulted in interest in the potential therapeutic role of manipulation of 
microbiota in IBS [31].
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Our previous studies have found alleviating effects of 
Lactobacillus paracasei on dextran sulfate sodium (DSS)-induced 
colitis mice and Lactobacillus plantarum on stress-related anxiety and 
depression in animal model separately. In this study, we evaluated and 
compared the effects between two different Lactobacillus strains and 
their combination on behavioral anxiety and inflammatory response in 
zymosan-induced IBS mouse model.
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II. Materials and Methods
1. Animals
Seven-week-old male specific pathogen-free (SPF) C57BL/6 
mice used in this study were purchased from Central Lab Animals 
Incorporated (Seoul, Korea). The performance and protocols of animal 
experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Seoul National University, Korea (Case 
Number: SNU-190110-2). Mice were housed under standard laboratory 
conditions under 12:12 light/dark cycle and 25 ± 2°C temperature and 
allowed free access to water and mice chow. Sixty-six mice were 
acclimated for 1 week before the test then randomly assigned into 6 
experimental groups (11 mice per group in 3 cages). In order to revise 
the cage effect, we performed the testing by dividing the mice into 
three groups in a group. We also performed the second testing with 
same method, amount, and a pilot testing in a similar environment.
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2. Bacteria preparation
L. plantarum KBL396 and L. paracasei KBL382 were 
obtained from fecal samples of healthy Korean Adults. A lyophilized 
combination of these two strains (L. plantarum KBL396 and L. 
paracasei KBL382), and individual strain L. plantarum KBL396 or L. 
paracasei KBL382 were prepared. Before administration, each single 
lyophilized strain was diluted in 10-fold and the number of colonies 
were counted by pour plate methods to measure their viability in the 
samples. These lyophilized bacteria were rehydrated in 1x phosphate-
buffered saline (PBS) at a concentration of 109 colony-forming units 
(CFU) per milliliter. The bacterial solution was administered orally 
using plastic feeding needle at similar times each day for every 3 weeks 
in mice before and during the experimental procedure (7 days prior to 
the starting the zymosan injection until they were sacrificed).
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3. Zymosan-induced IBS animal preparation and treatment
To induce IBS-like symptoms, a volume of 0.1 mL zymosan 
suspension (30 mg/mL in PBS; Sigma-Aldrich, St. Louis, MO, USA) 
was administered into the colons using a 22-gauge long stainless steel 
feeding needle. Mice were anesthetized by isoflurane inhalation during 
the performance. Either vehicle (PBS) or zymosan was given daily for 
3 consecutive days (days 1, 2, and 3). Naïve group was subjected to the 
same procedure as those in zymosan-induced control group except 
intracolonic injection with 0.1 mL PBS. Three groups of mice were 
pretreated with mixed strains or single strain of two Lactobacillus spp. 
for 7day prior to injection with PBS or zymosan while other groups 
were pretreated with PBS. Mice were divided into 6 groups (n = 11 per 
group): (1) oral administration of PBS plus intracolonic injection with 
saline (2) oral administration of PBS plus intracolonic injection with 
zymosan (3) oral administration of amitriptyline (AMT; 30 mg/kg, 
Sigma-Aldrich, St. Louis, MO, USA) plus intracolonic injection with 
zymosan (4) oral administration of L. plantarum KBL396 plus 
intracolonic injection with zymosan (5) oral administration of L. 
paracasei KBL382 plus intracolonic injection with zymosan (6) oral 
administration of combined two Lacrobacillus strains plus intracolonic 
8
injection with zymosan. This procedure is shown in Table 1 and Figure 
1.
9
Table 1. Treatment groups for in vivo study.
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Figure 1. Scheme of animal study. 
Oral administration was started 7 days prior to zymosan injection. Intracolonic injection of zymosan suspension was performed for 3
consecutive days. Behavioral tests were performed separately on day 6 and day 13 from the first day of zymosan injection. Mice were 
sacrificed the next day of behavioral testing. 
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4. Quantitative real-time PCR (RT-qPCR)
Total RNA from the distal colon, hippocampus, and prefrontal 
cortex was homogenized using Trizol solution. RNA was extracted with 
easy-spinTM Total RNA Extraction Kit (iNtRON biotechnology,
Seongnam-si, Korea) by provided manufacturer’s protocol. RNA was 
quantified and assessed purity using a NanoDrop ND2000 (Thermo 
Fisher Scientific, Illkirch, France). cDNA was synthesized from RNA 
samples with High Capacity RNA-to-cDNA kit (Thermo Fisher 
Scientific, Waltham, MA, USA). Amplicons were performed with 
Power SYBR Green PCR Master Mix (Thermo Fisher Scientific). 
GAPDH was used as a housekeeping gene to normalize reverse 
transcription- quantitative polymerase chain reaction (RT-qPCR) data to 
the expression levels. Reactions were duplicated for each run and the 
expression level was calculated by relative quantity (2–ΔΔCT) method. 
Primer sequences used in this study were listed in Table 1.
12
Table 2. RT-qPCR primers sequence used in this study.
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5. Enzyme-Linked Immunosorbent Assay (ELISA)
After collecting blood samples, Prefrontal cortex and 
hippocampus were collected and stored at –80 °C until use. Brain 
tissues and mucosal samples were separately homogenized in RIPA 
buffer (1:10 w/v, Sigma-Aldrich) containing protease inhibitors. The 
protein concentration of each sample was determined using PierceTM 
BCA Protein assay kit (Thermo Fisher Scientific). All samples were 
assayed in duplicate. The protein levels of BDNF were measured using 
a commercially available ELISA kit (R&D, Minneapolis, MN, USA) 
according to the manufacturer’s protocols. 
Blood was obtained and kept at room temperature for 30 min 
for clotting. Clotted samples were centrifuged at 1,800 rpm for 5 min at 
4°C, and then divided in aliquots and immediately stored at –80 °C 
until use. Concentration of protein of each sample were determined 
using PierceTM BCA Protein assay kit (Thermo Fisher Scientific) and 




Two classical behavior tests of anxiety, the open-field (OFT) 
and elevated plus maze (EPM), were performed and automatically 
analyzed using a video tracking system (SMART 3.0 PanLab software, 
Harvard Apparatus, Cambridge, MA, USA). The elevated plus maze is 
one of the most commonly used tests to measure anxiety-like behavior 
in the rodent model. Behavioral tests were performed separately on day 
6 and day 13 from the first day of zymosan injection. Before starting
any behavioral test, mice were habituated to the procedure room for 30 
min. During the test trials, two experimenters and the computer were 
behind a curtain to separate from the mice in the testing area. The 
testing area was illuminated with dim and indirect room light. The same 
conditions were used for both tests.
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7. Open field test
The open field maze is a white polystyrene box (44 cm ´ 44 
cm ´ 60 cm) with an enclosed wall. In this study, a multiple unit open 
field maze with four activity arenas were used and analyzed at one time. 
To remove scent clues, each box was empty and wiped with 95% 
ethanol after each test. The ethanol was allowed to evaporate and then 
each mouse was placed in the center of the box. The test was run for 5 
min. Follows were analyzed using a video tracking system (SMART 
3.0 PanLab software, Harvard Apparatus, Cambridge, MA, USA): (1) 
total distance traveled (2) distance traveled in the central zone (3) time 
spent in the central zone versus total time (4) number of entries in 
central zone.
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8. Elevated plus maze
The elevated plus maze is a plus-shaped apparatus consisted of 
two open arms and two closed arms in line. The maze was raised 50 cm 
above from the floor. At start of each test, individual mice were placed 
on the center facing an open arm. Mice were allowed to freely travel on 
the maze for 5 min while the frequency and time spent in open and 
closed arms is recorded. experimental area of the maze was cleaned 
with 95% ethanol every time before subsequent tests.
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9. Statistical analysis
All values are expressed as means ± standard error of the mean 
(SEM). GraphPad Prism 5.01 (GraphPad Software, San Diego, CA, 
USA) was used to evaluate analysis and graph all data. One-tailed 
Mann-Whitney U-test and one or two-way ANOVAs were performed 
with GraphPad Software. Differences in means and scopes were 
evaluated by t-tests and Fisher’s exact tests. Differences were 
considered significant when P < 0.05. Statistical significance was 
presented as ‘*’ P < 0.05, ‘**’ P < 0.01, ‘***’ P < 0.001.
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III. Results 
1. Pretreatment of L. plantarum KBL396 and L. paracasei KBL382 
has an impact on phenotypic characteristics in zymosan-induced 
mice
Previous studies have reported that zymosan-induced IBS 
mouse model is characterized by significant loss of body weight and a 
low-grade systemic toxicity [32]. To evaluate the effect of 
administration of two Lactobacillus strains in colon length, we 
measured the length of the colon of each mouse from the proximal 
colon to the anus. On day 7, injection of zymosan was associated with 
significantly decreased colon length while administration of two 
Lactobacillus strains prevented decreased colon length (Fig. 2A). The 
results of measured colon length on day 14 was similar to day 7 (Fig. 
2B). We also monitored weight and its changes in mice for 14 days 
after zymosan or normal saline injection. We found that oral 
administration of Lactobacillus strains effect in body weight, decreased 
the loss of body weight caused by zymosan (Fig. 2C). Administration 
of L. plantarum KBL396 significantly improved the body weights 
compared to control. However, AMT administration exhibited the 
accelerated loss of body weight and associated with the lowest body 
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weight gain among groups (Fig. 2C). Overall, administration of these 




Figure 2. Effects of L. plantarum KBL396 and L. paracasei KBL382 pretreatment on phenotypic characteristics in 
zymosan-induced IBS mice. 
(A) The colon length of each group was measured on day 7 and (B) day 14 separately after they were sacrificed. (C) The 
bodyweights of six groups (see Table 1 for groups) of mice (n = 11/group) were measured on day 0 before zymosan injection 
and every day until study is over. Statistical analysis was performed using a one-tailed unpaired t test. Data are presented as 
mean ± standard error of mean (SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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2. L. plantarum KBL396 and L. paracasei KBL382 treatment 
changes dysregulated cytokine response in IBS-like animal model
To evaluate the role of L. plantarum KBL396 and L. paracasei
KBL382 in the immune response caused by zymosan, we measured the 
level of proinflammatory cytokines (IL-1β and TNF-α) in the colon 
using RT-qPCR. Mice with IBS-like symptoms by zymosan injection 
displayed increased level of proinflammatory cytokine TNF-α 
compared to normal saline injected mouse on days 7 and 14 (Fig. 3). 
However, expression of IL-1β showed no difference between saline 
intracolonic injected group and zymosan intracolonic injected group 
with PBS oral administration on day 14 (Fig. 3D). In contrast to the 
saline injected mice, AMT and single strain administration group with 
zymosan showed significant differences in IL-1β level on both days 
compared to the control group (Fig. 3B & 3D). In addition, AMT and 
single strain administration group with zymosan attenuated the levels of 
TNF-α on day 14 (Fig. 3C). The combination group of two 
Lactobacillus strains also suppressed TNF-α and IL-1β at day 7. (Fig. 
3A & 3B). These results show that Lactobacillus strains can show the 




Figure 3. Effects of L. plantarum KBL396 and L. paracasei KBL382 pretreatment on different levels of inflammatory cytokines in the 
colon.
Relative expression levels of proinflammatory cytokines were analyzed by RT-qPCR in zymosan-induced IBS mice and saline-treated mice.
The levels of (A) TNF-α and (B) IL-1β in the colon were determined at day 7. The levels of (C) TNF-α and (D) IL-1β expression were 
determined at day 14. Values represent the mean of at least 8 animals ±SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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3. Colonic mucosal BDNF, serotonin, and serotonin transporter 
level are affected by administration of L. plantarum KBL396 and L. 
paracasei KBL382 in mice
Recent study has shown that brain-derived neurotrophic factor 
(BDNF) is modulated by gut microbiota in the CNS [33] and increased 
expression of BDNF in colonic mucosa has been found in IBS patients 
[19-22]. To determine the role of L. plantarum KBL396 and L. 
paracasei KBL382 in the mucosal BDNF level, relative expression 
levels of BDNF in the distal colon were measured by RT-qPCR at days 
7 and 14. BDNF expressions in the colon were significantly increased 
in the zymosan injected control mice compared to normal saline 
injected mice. Moreover, all three different treatment groups with 
Lactobacillus strains showed a significant decrease in the mucosal 
BDNF level, while AMT treated mice showed similar BDNF mRNA 
level to control mice in the colon on day 7 (Fig. 4A). This trend 
continued until day 14 except the AMT treated group which showed 
significant decrease in levels of BDNF in colonic mucosa (Fig. 4D). In 
patients with IBS, it has been reported that 5HT3 antagonists can 
reduce the visceral hypersensitive, which is a hallmark characteristic of 
IBS, by preventing the activation of 5HT3 receptor [34]. In this study, 
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only a slight difference was observed for 5HT3A mRNA level on day 7 
in colon (Fig. 4B). However, it was significantly increased in AMT and 
L. plantarum KBL396 treated mice on day 14 (Fig. 4E). On the other 
hand, control mice showed the decreased level of SERT1 expression 
compared to other different treated groups on both days (Fig. 4C & 4F). 
In addition, three groups administered with Lactobacillus showed a 
significantly higher level of SERT1 compared to control group (Fig. 
4F). Notably, the lowest level of mucosal BDNF was seen in the group 
treated with the combination of the two strains at day 7 and the highest 
level of SERT1 at day 14 in colonic mucosa. 
27
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Figure 4. Different levels of Brain-derived neurotrophic factor (BDNF), serotonin receptor (5HT3A), and serotonin transporter 
(SERT1) in the colon of six groups of mice under different treatments. 
Relative expression levels of mRNA in the distal colon were determined by RT-qPCR at days 7 and 14. (A) Total BDNF, (B) 5HT3A, and (C) 
SERT1 levels were measured on day 7. (D) Total BDNF, (E) 5HT3A, and (F) SERT1 levels were measured on day 14. Statistical analysis was 
performed using t test and values represent the mean of at least 8 animals ±SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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4. L. plantarum KBL396 and L. paracasei KBL382 treatment effect 
on changes in the expression of BDNF and serotonin level in the 
hippocampus and prefrontal cortex
Recent study has shown that administration of probiotics can 
modulate levels of BDNF in the brain [35, 36]. To investigate the 
effects of selected Lactobacillus strains and the combination of these 
two strains on BDNF in IBS-like mice, BDNF total variant and BDNF 
exon IV expression in the hippocampus and prefrontal cortex were 
measured by reverse transcription polymerase chain reaction (RT-PCR) 
at days 7 and 14. Zymosan injected control mice had a significant 
increase in both BDNF total variants and BDNF exon IV compared to 
normal saline injected mice on day 7, while there was no significant 
differences between two groups on day 14 (Fig. 5). The combination of 
two Lactobacillus strains increased both BDNF total variants and 
BDNF exon IV significantly on day 14 (Fig. 5D and 5E), while 
decreased BDNF exon IV on day 7 in zymosan-induced mice (Fig. 5B). 
Depression is associated with IBS in bidirectional gut-brain 
communication [37] and it is well known that decreased levels of 
serotonin in the brain caused a decreased mood [38]. Zymosan injected 
control mice showed a significant decrease in 5HT3A compared to 
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other treatment groups, except AMT treated mice, on day 14 (Fig. 5F).  
Although there were no significant changes in 5HT3A between groups 
(Fig. 5C), three groups administered with Lactobacillus showed a 
higher level of 5HT3A tendency than zymosan injected control group.
The results obtained showed that L. plantarum KBL396 and L. 




Figure 5. Different levels of Brain-derived neurotrophic factor (BDNF), BDNF4, and serotonin receptor (5HT3A) in the hippocampus 
(HPC) and prefrontal cortex (PFC) of six groups of mice under different treatments. 
Relative expression levels of mRNA in the brain region were determined by RT-qPCR at days 7 and 14. (A) Total BDNF, (B) BDNF4, and (C) 
5HT3A levels were measured on day 7. (D) Total BDNF, (E)BDNF4, and (F) 5HT3A levels were measured on day 14. Statistical analysis was 
performed using t test and values represent the mean of at least 8 animals ±SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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5. Administration of L. plantarum KBL396 and L. paracasei
KBL382 effects on anxiety-like behavior in the open filed test
Several studies have found that the administration of the 
combination of probiotic gut bacteria have an impact on brain functions 
as well as anxiety [39, 40]. In the open field test, the lower number of 
entries into the central zone was observed in the combination group 
compared to the control group, while the travel distance within and the 
time spent in central zone were increased slightly on day 6 (Fig. 6). 
However, no significant change was observed amongst the two groups 
on day 13. A higher number of entries into the central zone was 
observed on both days in the AMT group. There was no statistically 
significant difference between L. paracasei KBL382 treated and 
control group except L. paracasei KBL382 treated mice spent more 
time in the central zone on day 6 (Fig. 6E). Finally, administration of L. 




Figure 6. Effects of L. plantarum KBL396 and L. paracasei KBL382 treatment on behavioral assessment of zymosan-treated mice in 
the open field (OFT). 
The number of entries into the central zone was counted for 5 min in the open field test on (A) day 6 and (B) day 13. The distance traveled in 
the central zone was measured for 5 min in the open field test on (C) day 6 and (D) day 13. The percentage of relative stay in the central zone 
was measured for 5 min in the open field test on (E) day 6 and (F) 13. Statistical analysis was performed using one-way ANOVA and data are 
presented as mean ± standard error of mean (SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.00
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6. Administration of L. plantarum KBL396 and L. paracasei
KBL382 effects on anxiety-like behavior in the elevated plus maze 
test
In the elevated plus maze test, mice administered with the 
combination of two Lactobacillus strains showed increased the distance 
travelled in and time spent on the open arms in comparison with control 
mice injected with zymosan, although no significant differences were 
found in the number of entries into the open arms between two groups 
on days 6 and 13 (Fig. 7). Mice administered with L. plantarum
KBL396 showed the higher number of entries into the open arms day 6 
and 13 (Fig. 7A & 7B). Also, the increased travel distance and time 
spent on the open arms were observe in this group compared to control 
mice injected with zymosan on day 13 (Fig. 7D & 7F). Mice 
administered with L. paracasei KBL382 showed the higher number of 
entries, increased the distance travelled, and more time spent on the 
open arms compared to control mice injected with zymosan on day 6, 
while no significant differences were observed on day 13 in comparison 
with control mice injected with zymosan.
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Figure 7. Effects of L. plantarum KBL396 and L. paracasei KBL382 
treatment on behavioral assessment of zymosan-treated mice in elevated 
plus maze (EPM).
The number of entries into open arms was scored for 5 min in the elevated 
plus maze on (A) day 6 and (B) day 13. The distance traveled in the open 
arms was measured for 5 min in the elevated plus maze on (C) day 6 and (D) 
13. The percentage of relative stay in the open arms was measured for 5 min 
in the elevated plus maze on (E) day 6 and (F) day 13. Statistical analysis was 
performed using one-way ANOVA and data are presented as mean ± standard 
error of mean (SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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IV. Discussion
In the present study, we examined the administration of two 
selected Lactobacillus strains and its beneficial effects in zymosan-
induced IBS mice. Our results included three major findings: (1) 
decreased expression of proinflammatory cytokines TNF-α and IL-1β 
in the colons of mice administered with Lactobacillus strains 
demonstrated that probiotic gut bacteria modulate the immune response 
and improve low-grade inflammation in IBS. (2) Decreased level of 
BDNF and increased level of SERT1 expression in the colons of mice 
administered with Lactobacillus strains showed treatment of L. 
plantarum KBL396 and L. paracasei KBL382 help alleviate IBS 
symptoms, such as visceral hypersensitivity. (3) Increased mRNA
expression of 5HT3A in brain and reduced anxiety-like behavior in the 
elevated plus maze test in mice administered with the combination of 
two Lactobacillus strains indicate that treatment of the combination of 
L. plantarum KBL396 and L. paracasei KBL382 has an impact on 
brain chemistry and psychological features of IBS in bidirectional 
interactions within the brain-gut-microbiota axis. The findings of this 
study suggest that probiotic gut microbiota, especially Lactobacillus 
plantarum KBL396 and Lactobacillus paracasei KBL382, can play an 
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important role in improving symptoms and psychiatric morbidity 
associated with IBS.
Some evidence studies have reported that administration of 
combined probiotic Lactobacillus and Bifidobacterium spp. have
significant beneficial effects on abdominal pain, delayed colonic transit, 
and bloating [39 - 41]. Furthermore, recent study has shown that 
pretreatment of the combination of two probiotics Bifidobacterium
longum R0175 and Lactobacillus helveticus R0052 has more efficacy 
in reducing the chronic stress-induced visceral hypersensitivity than 
pretreatment with single strain alone in mice [42]. Our previous work 
demonstrated that Lactobacillus plantarum KBL396 can prevent
depressive-like behavior and diminish immune changes induced by 
chronic social defeat stress in mice. In addition, it was confirmed that 
treatment of Lactobacillus paracasei KBL382 can help reduce the signs 
and symptoms of inflammation in a DSS-induced colitis mouse model. 
These findings suggest that administration of combined L. plantarum
KBL396 and L. paracasei KBL382 may have positive effects on IBS-
like symptoms in mice since IBS is related with the dysfunctional gut-
brain-microbiome axis. In this study, we demonstrated that pretreatment 
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of mixed strains of two Lactobacillus strains display reduced 
proinflammatory properties in zymosan-induced low grade 
inflammation in mice on days 7 and 14 (Fig. 3). In animal study, it has 
been reported that proinflammatory cytokines TNF-α can induce 
psychiatric-like symptoms [43]. Interestingly, mice pretreated with 
single strain of Lactobacillus showed increased TNF-α mRNA 
expression on day 7, while TNF-α level was decreased on day 14 in 
comparison with control mice. However, little is known about the 
specific mechanisms underlying the anti-inflammatory effects of 
intestinal microbiome. Therefore, further studies are necessary to fully 
understand this.
Numerous studies have shown that increased production of 
BDNF in colonic mucosa contributes to IBS-like colonic 
hypersensitivity [20, 21, 44]. In previous study, BDNF knockdown or 
tyrosine receptor kinase B (TrkB) inhibitor, also known as the high-
affinity receptor of BDNF inhibitor, reduces visceral hypersensitivity in 
mice [21]. Our study demonstrates that mice treated with mixed and 
single strain of Lactobacillus exhibited decreased mucosal BDNF 
expression in colon (Fig. 4A & 4D). On the contrary, deceased SERT 
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expression has been reported in IBS patients [45, 46]. The serotonin 
transporter terminates serotonergic signaling of serotonin by sodium-
and chloride- dependent reuptake [47]. In this study, we convincedly 
demonstrated that level of SERT expression increases significantly in 
mice that administered with mixed and single strain of L. plantarum
KBL396 and L. paracasei KBL382 on day 14 (Fig. 4F). However, 
there was no statistically significant change in the expression of 5HT3A 
between the groups (Fig. 4B &4E). Although no significant differences 
were seen in level of 5HT3A mRNA in the colon, we found statistically 
significant changes in 5HT3A levels in brain (Fig. 5F). Indeed, it has 
been suggested that gut microbiota can influence brain chemistry. In 
brain, serotonin (5-HT) plays an important role in the mood and its 
activation shows negative correlation with anxiety and depression [48]. 
It is also well recognized that the 5-HT3 receptor antagonists are used 
for the treatment of IBS symptoms as the 5HT3A polymorphism is 
associated with IBS [49]. Our results showed a significant increase in 
level of 5HT3A expression in the brain of mice that treated with mixed 
and single strain of L. plantarum KBL396 and L. paracasei KBL382 on 
day 14 (Fig. 5D). It was also observed that pretreatment of the 
combination of the two Lactobacillus strains produced significant 
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increase in BDNF and BDNF exon IV expression in the brain (Fig. 5D 
& 5E). Interestingly, it has been reported that oral administration of 
probiotics increases BDNF expression in brain and shows a significant 
anxiolytic effect [50].
It is becoming increasingly evident that gut microbiota can 
influence brain function and behavior [51-53]. In several studies, pain 
and anxiety behaviors in zymosan-induced animal model of IBS have 
been reported [54-56]. In this study, we found that single strain of L. 
plantarum KBL396-treated mice experienced less anxiety compared to 
control mice, as measured by the number of entries, distance traveled, 
and time spent in the central zone in the open field test on day 13 (Fig. 
6). Interestingly, mice treated with mixed and single strain of L. 
plantarum KBL396 and L. paracasei KBL382 display reduced anxiety-
like behavior, as measured by the number of entries, distance traveled, 
and time spent in the open arms using elevated plus maze. (Fig. 7). 
These results collectively suggest that L. plantarum KBL396 and L. 
paracasei KBL382 have anxiolytic effects on anxiety-like behaviors. 
However, no statistically significant difference was observed between 
groups. In the same group there were deviations within the group of 
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mice, as a result there were too little number of mice to show the 
statistical significance of the tests. In order to show the statistical 
significance, a retest need to be performed with greater number of mice.
Therefore, other environmental factors influencing the animal’s 
behavior and movement need to be more carefully controlled to 
minimize variations of individual mice within the same group.
In summary, our study shows that treatment with either mixed 
or single strain of L. plantarum KBL396 and L. paracasei KBL382 
reduces colonic inflammation and alters chemistry associated with 
visceral hypersensitivity in gut-brain axis in zymosan-induced mouse 
model of IBS. Our findings provide a base for further research on 
therapeutic solution for the treatment of IBS.
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[Appendix 1] Supplementary figure 1
Supplementary Figure 1. Brain Bdnf level 
Mean BDNF in the brain region were determined by ELISA at (A) day 7 and 
(B) day 14. Statistical analysis was performed using t test and values represent 
the mean of at least 8 animals ±SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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[Appendix 2] Abbreviation
Supplementary Figure 2. Level of IL-6 and IFN-γ (colon) in serum
Level of IL-6 and IFN-γ in serum were determined by ELISA at day 7. (A)
IL-6 is downregulated in the combination group. (B) IFN-γ level is decreased 
in the combination group in serum. Statistical analysis was performed using t 
test and values represent the mean of at least 5 animals ±SEM. *, P < 0.05; **, 
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Central nervous system (CNS)
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Irritable bowel syndrome (IBS)
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과민성 장 증후군은 가장 흔한 기능성 위장관 장애로
전세계적으로 유병률이 증가하고 있다. 과민성 장 증후군 환
자에서는 복통과 배변 습관 변화 등의 이상 뿐만 아니라 불
안장애와 우울증과 같은 정신과적 증상이 동반되는 것으로
알려져 있다. 그럼에도 불구하고 아직까지 확실한 치료법이
없어 단기적으로 증상을 개선시키는 치료밖에 없는 실정이다. 
그러나 최근에는 과민성 장 증후군 환자에서 장내 미생물군
총과 그 기능이 변화되는 것이 밝혀지면서 장내 미생물이 과
민성 장 증후군에서 장-뇌 축을 따르는 중요한 병리 생리학
적 요소임이 알려졌다. 특히, 과민성 장 증후군 환자에서 일
반적으로 락토바실러스와 비피도박테리움 종이 감소하는 것
으로 확인되었다. 본 연구에서는 과민성 장 증후군 마우스 모
델에서 락토바실러스 플란타룸 KBL396과 락토바실러스 파
라카제이 KBL382의 혼합 및 단일 균주의 효능 및 효과를
확인하고자 하였다. 마우스에 과민성 장 증후군과 같은 증상
을 유도하기 위해 자이모산 현탁액을 3일간 연속적으로 항문
주사 하였다. 락토바실러스 플란타룸 KBL396과 락토바실러
스 파라카제이 KBL382를 투여한 마우스에서 자이모산 주입
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후 각각 7일차와 14일차에 대장과 뇌에서 염증성 사이토카인
의 감소 및 뇌유래신경영양인자 및 신경전달물질의 mRNA 
발현량이 변화되는 것을 확인하였다. 또한, 고가식 십자미로
와 오픈 필드 평가를 통해 두 락토바실러스 균주를 혼합 또
는 단일로 투여한 마우스에서 불안 장애를 나타내는 행동이
감소되는 것을 확인하였다. 이러한 결과는 락토바실러스 플란
타룸 KBL396과 락토바실러스 파라카제이 KBL382가 마우스
에서 과민성 장 증후군 증상을 완화시키고 불안 장애와 같은
행동을 개선할 수 있음을 보여주고 있다.
주요 단어: 불안장애 행동, 장-뇌 축, 과민성 장 증후군, 락토
바실러스, 장내 미생물, 자이모산
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